Lilly, OrbiMed back China cancer upstart InventisBio in $19M series B by Ben Adams Wednesday, May 31, 2017 Shanghai-based cancer and gout biotech InventisBio has raised $19 million in a series B financing, just a year after its $11 million series A, with the cash injection being led by OrbiMed Asia Partners and original backer Lilly Asia Ventures.
